MAP Pharmaceuticals, Inc.
today announced that it will present Phase 2 data from its MAP0004 migraine
therapy clinical program at the 49th Annual American Headache Society
Meeting at the Hyatt Regency Chicago in Chicago, Illinois. The poster
presentation, which was accepted as a late-breaker, is entitled Rapid and
Sustained Clinical Efficacy and Safety of Inhaled Dihydroergotamine
Mesylate via a Novel Inhaler (Tempo(TM) Inhaler), Poster ID S77, and will
be presented on Saturday, June 9, 2007 from 12:00 to 1:00pm CDT. In
addition, the Company also has three other poster presentations available
for viewing at the conference.
Details for the three presentations are as follows:
-- Clinical Safety of Inhaled Dihydroergotamine Mesylate via a Novel
System (Tempo(TM) Inhaler); Poster ID F07; June 8, 12:30 to 1:30pm CDT.
-- Comparative Clinical Pharmacokinetics of Parent Drug and Metabolites
Following Inhaled Dosing with Dihydroergotamine Mesylate via a Novel
System (Tempo(TM) Inhaler); Poster ID F08; June 8, 12:30 to 1:30pm CDT.
-- (5-HT, Adrenergic, Dopaminergic) Receptor Binding: Implications for
Inhaled Dosing with Dihydroergotamine Mesylate via a Novel System
(Tempo(TM) Inhaler); Poster ID S67; June 9, 12:00 to 1:00pm CDT.
MAP Pharmaceuticals is developing a series of inhaled respiratory and
systemic drug product candidates delivered with the Tempo inhaler. The
first of these product candidates is MAP0004, a systemic migraine treatment
designed to provide faster and more consistent relief than current
non-injectable therapeutics. In early human studies, MAP0004 delivered
therapeutic blood levels within ten minutes of inhalation, similar to those
seen only after intravenous injection. This performance will potentially
allow MAP0004 to mimic both the efficacy and blood levels of injectable
therapy, offering fast relief without injections. By providing rapid onset
with a novel formulation of a proven compound (dihydroergotamine mesylate),
MAP Pharmaceuticals seeks to meet the treatment needs of the large,
underserved population of migraine sufferers with MAP0004.
About MAP Pharmaceuticals
Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a
privately-held biopharmaceutical company focused on developing novel
treatments for respiratory and neurological diseases. The Company has
announced positive results from Phase 2 clinical trials in two development
programs: a proprietary formulation of nebulized budesonide for the
potential treatment of children with asthma, and a proprietary formulation
of inhaled dihydroergotamine for the potential treatment of migraines.
Additional information about MAP Pharmaceuticals can be found at
mappharma.
MAP Pharmaceuticals, Inc.
mappharma